Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002356 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002356: Completed Phase 2 study, sponsored by Ionis Pharmaceuticals.
NCT00002356 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002356, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwise ineligible for ISIS Pharmaceuticals' controlled trials OR who have failed ISIS 2922 therapy on another controlled clinical trial. PER 2/8/96 AMENDMENT: Patients must rollover from another ISIS 2922 controlled trial.
Interventions
- DRUG Fomivirsen sodium
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00002356 record still lists
NCT00002356 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Fomivirsen sodium is the first listed.
NCT00002356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002356 about?
NCT00002356 is a clinical study titled "The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes". To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwise ineligible for ISIS Pharmaceuticals' controlled trials OR who have failed ISIS 2922 therapy on another control...
What is the current status of trial NCT00002356?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002356?
The interventions under investigation include: Fomivirsen sodium (DRUG).
Who is sponsoring clinical trial NCT00002356?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.